

Special Issue

Advances in Universal Influenza Vaccines and Therapies

Message from the Guest Editors

Seasonal and emerging influenza viruses have major implications for public health. Seasonal influenza A and B viruses are associated with high rates of illness and hospitalization each year, and vaccine strategies vary in efficacy year to year. Additionally, influenza viruses can lead to (and, in fact, have led to) pandemics, and the development of new, innovative strategies to improve protection against both seasonal and pandemic influenza viruses remains a high priority. This Special Issue aims to describe recent strategies that target influenza with vaccines and to understand and predict the corresponding immunological responses. Subtopics of interest include, but are not limited to:

- Influenza A and B virus vaccines;
- Full-length and engineered forms of viral antigens;
- General and high-risk host populations;
- Universal influenza vaccine design;
- Conventional and novel antigens;
- Conventional and novel platforms for vaccine development;
- Conventional and novel adjuvants/ formulations/ routes and technologies for delivery;
- Immune effectors/mechanisms and correlates of protection.

Guest Editors

Dr. Charles J. Russell

Dr. Julia L. Hurwitz

Dr. Jarrod J. Mousa

Deadline for manuscript submissions

closed (1 September 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/112747

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).